(VBK) VERBIO Vereinigte BioEnergie - Overview
Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: XETRA (Germany) | Market Cap: 2.401m EUR | Total Return: 26.2% in 12m
Avg Turnover: 5.10M
Qual. Beats: 0
Rev. Trend: -47.3%
Warnings
Interest Coverage Ratio -2.5 is critical
Below Avwap Earnings
Tailwinds
Confidence
Verbio SE is a German-based producer and distributor of biofuels and bio-based chemicals, operating through Biodiesel, Bioethanol/Biomethane, and Other segments. The company processes agricultural raw materials into renewable fuels, animal feed, fertilizers, and pharmaceutical-grade glycerine. Its business model focuses on a closed-loop refinery system where waste products from one process serve as feedstock for another, maximizing resource efficiency.
The company serves diverse sectors including transportation, energy utilities, and the pharmaceutical industry across Europe and North America. As a player in the specialty chemicals and renewable energy sectors, Verbio is subject to regulatory frameworks like the European Unions Renewable Energy Directive (RED II), which mandates specific greenhouse gas reduction targets for transport fuels. The company recently transitioned to a European Company (SE) legal structure to reflect its increasing international operations.
For deeper insights into the companys valuation metrics, consider reviewing the detailed data available on ValueRay.
- European biofuel demand hinges on EU Renewable Energy Directive policy shifts
- Fluctuating feed and grain prices directly impact production margins and profitability
- Expansion of North American biomethane capacity drives long-term revenue growth potential
- Greenhouse gas reduction quota prices in Germany dictate biodiesel segment earnings
- Global crude oil price volatility influences competitive pricing of renewable fuels
| Net Income: -75.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 8.60 > 1.0 |
| NWC/Revenue: 14.55% < 20% (prev 17.33%; Δ -2.79% < -1%) |
| CFO/TA 0.09 > 3% & CFO 121.8m > Net Income -75.0m |
| Net Debt (204.8m) to EBITDA (90.2m): 2.27 < 3 |
| Current Ratio: 1.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (63.7m) vs 12m ago -0.86% < -2% |
| Gross Margin: 7.03% > 18% (prev 14.87%; Δ -7.85% > 0.5%) |
| Asset Turnover: 132.3% > 50% (prev 107.4%; Δ 24.88% > 0%) |
| Interest Coverage Ratio: -2.45 > 6 (EBIT TTM -43.0m / Interest Expense TTM 17.5m) |
| A: 0.20 (Total Current Assets 540.8m - Total Current Liabilities 282.8m) / Total Assets 1.30b |
| B: 0.17 (Retained Earnings 220.0m / Total Assets 1.30b) |
| C: -0.03 (EBIT TTM -43.0m / Avg Total Assets 1.34b) |
| D: 1.46 (Book Value of Equity 768.8m / Total Liabilities 527.3m) |
| Altman-Z'' = 3.17 = A |
| DSRI: 0.91 (Receivables 112.0m/103.6m, Revenue 1.77b/1.49b) |
| GMI: 2.12 (GM 14.87% / 7.03%) |
| AQI: 0.22 (AQ_t 0.00 / AQ_t-1 0.02) |
| SGI: 1.19 (Revenue 1.77b / 1.49b) |
| TATA: -0.15 (NI -75.0m - CFO 121.8m) / TA 1.30b) |
| Beneish M = -2.43 (Cap -4..+1) = BBB |
As of June 08, 2026, the stock is trading at EUR 37.68 with a total of 45,322 shares traded.
Over the past week, the price has changed by -3.79%,
over one month by +0.24%,
over three months by +9.91% and
over the past year by +26.20%.
VERBIO Vereinigte BioEnergie has no consensus analysts rating.
P/E Forward = 6.7385
P/S = 1.3478
P/B = 3.1278
P/EG = 5.8004
Revenue TTM = 1.77b EUR
EBIT TTM = -43.0m EUR
EBITDA TTM = 90.2m EUR
Long Term Debt = 175.9m EUR (from longTermDebt, last quarter)
Short Term Debt = 28.6m EUR (from shortTermDebt, last quarter)
Debt = 259.6m EUR (from shortLongTermDebtTotal, last quarter) + Leases 32.1m
Net Debt = 204.8m EUR (calculated: Debt 259.6m - CCE 54.9m)
Enterprise Value = 2.61b EUR (2.40b + Debt 259.6m - CCE 54.9m)
Interest Coverage Ratio = -2.45 (Ebit TTM -43.0m / Interest Expense TTM 17.5m)
EV/FCF = 115.8x (Enterprise Value 2.61b / FCF TTM 22.5m)
FCF Yield = 0.86% (FCF TTM 22.5m / Enterprise Value 2.61b)
FCF Margin = 1.27% (FCF TTM 22.5m / Revenue TTM 1.77b)
Net Margin = -4.23% (Net Income TTM -75.0m / Revenue TTM 1.77b)
Gross Margin = 7.03% ((Revenue TTM 1.77b - Cost of Revenue TTM 1.65b) / Revenue TTM)
Gross Margin QoQ = 13.10% (prev 17.38%)
Tobins Q-Ratio = 2.01 (Enterprise Value 2.61b / Total Assets 1.30b)
Interest Expense / Debt = 6.75% (Interest Expense 17.5m / Debt 259.6m)
Taxrate = 46.75% (20.1m / 43.1m)
NOPAT = -22.9m (EBIT -43.0m * (1 - 46.75%)) [loss with tax shield]
Current Ratio = 1.91 (Total Current Assets 540.8m / Total Current Liabilities 282.8m)
Debt / Equity = 0.34 (Debt 259.6m / totalStockholderEquity, last quarter 768.8m)
Debt / EBITDA = 2.27 (Net Debt 204.8m / EBITDA 90.2m)
Debt / FCF = 9.10 (Net Debt 204.8m / FCF TTM 22.5m)
Total Stockholder Equity = 750.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.59% (Net Income -75.0m / Total Assets 1.30b)
RoE = -10.00% (Net Income TTM -75.0m / Total Stockholder Equity 750.3m)
RoCE = -4.64% (EBIT -43.0m / Capital Employed (Equity 750.3m + L.T.Debt 175.9m))
RoIC = -2.32% (negative operating profit) (NOPAT -22.9m / Invested Capital 987.0m)
WACC = 6.59% (E(2.40b)/V(2.66b) * Re(6.91%) + D(259.6m)/V(2.66b) * Rd(6.75%) * (1-Tc(0.47)))
Discount Rate = 6.91% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 4.49 | Cagr: -9.82%
[DCF] Terminal Value 75.44% ; FCFF base≈22.5m ; Y1≈22.6m ; Y5≈23.9m
[DCF] Fair Price = 2.63 (EV 372.2m - Net Debt 204.8m = Equity 167.5m / Shares 63.7m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.76 | # QB: 0
Revenue Correlation: -47.33 | Revenue CAGR: -4.54% | SUE: N/A | # QB: 0
EPS current Year (2026-06-30): EPS=0.76 | Chg30d=+46.73% | Revisions=+25% | GrowthEPS=+135.0% | GrowthRev=+13.6%
EPS next Year (2027-06-30): EPS=1.89 | Chg30d=+18.11% | Revisions=+43% | GrowthEPS=+149.3% | GrowthRev=+11.8%
[Analyst] Revisions Ratio: +43%